Cited by 3Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Multi-omics reveals changes in astrocyte fatty acid metabolism during early stages of Alzheimer's disease

Open access
Zhong, Jie, Li, Manhui, Dai, Ziwei, Wan, Jun·2025·Neurochemistry International

Abstract

BACKGROUND: Although astrocytes are known to contribute to Alzheimer's disease (AD) progression, their dynamic molecular alterations remain poorly characterized, particularly in early stages of the disease. METHODS: We performed multi-omics profiling (transcriptomics, proteomics, spatial metabolomics) of astrocytes from APP/PS1 and WT mice to characterize dynamic changes during AD progression. To assess similar changes in early human AD, we analyzed single-nucleus RNA sequencing data from human samples. RESULTS: Transcriptomic analysis of astrocytes from APP/PS1 and WT mice at five time points (2, 4, 6, 9, and 12 months of age) showed notable gene expression differences at 6 months, with reduced activity in fatty acid metabolism pathways (e.g., PPAR signaling, biosynthesis of unsaturated fatty acids). An astrocyte-specific metabolic model confirmed these disruptions. Proteomic analysis corroborated this by showing decreased activity in pathways like butanoate metabolism and PPAR signaling. Spatial metabolomics of brain slices from APP/PS1 and WT mice highlighted fatty acid enrichment in the hippocampus and cortex, alongside differential metabolites specific to the AD mouse model. Single-cell RNA sequencing analysis of human brain samples further showed fatty acid metabolism abnormalities in astrocytes from early AD cases versus controls, emphasizing its role in AD progression. CONCLUSION: Our study identified abnormal fatty acid metabolism as an early feature of astrocytes in AD, suggesting an association between dysregulated fatty acid metabolism and disease progression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuint.2025.106049

Cites

92 of 92 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Zhong, J., Li, M., Dai, Z., & Wan, J.
Affiliations
  • Hong Kong University of Science and Technology (HK)
  • Southern University of Science and Technology (CN)
  • Peking University (CN)
Corresponding author
  • Dai, Ziwei
  • Wan, Jun
Venue
Neurochemistry International
Publisher
Elsevier BV
Published
2025-11
Volume
190
Pages
106049
ISSN
0197-0186 (ISSN-L)
OpenAlex
W4413840496
Cited by
3
References
89
Citations by year
2026: 3
FWCI
1.94
Type
journal article
Language
en
Open access
Locations
  • Neurochemistry International (publishedVersion, cc-by-nc-nd)
  • Research Square (acceptedVersion, cc-by)
  • PubMed (publishedVersion)
  • Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
Funders
  • Shenzhen Technology Development Program (JCYJ20220818100215033)
  • Guangxi Natural Science Foundation (2020GXNSFDA238009)
  • National Natural Science Foundation of China (82071586, 12371489)
  • National Key Research and Development Program of China (2021YFF1201000)
  • Guangdong Innovative and Entrepreneurial Research Team Program (2021ZT09Y104)
  • Southern University of Science and Technology
  • Defense Health Agency
  • Amazon Research Awards
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, astrocytes, fatty acid metabolism, early-stage disease, APP/PS1 mice, PPAR signaling, unsaturated fatty acid biosynthesis, butanoate metabolism, hippocampus, cortex, single-nucleus RNA sequencing, multi-omics
MeSH terms
Multiomics, Alzheimer Disease, Animals, Astrocytes, Fatty Acids, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Proteomics, Mice, Metabolomics, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review